Nvlx

BUSINESS SUMMARY Nuvilex Inc., through its subsidiaries, engages in the research, development, and marketing of nutraceutical products in the United States and internationally. It has researched and developed a range of whole foods and nutraceutical products to help improve various health conditions, including glucose metabolism, scarring, acne, cholesterol, common cold, influenza, and other known pathogens, such as staphylococcus and streptococcus. The company?s lead product includes Cinnergen, a liquid whole food nutritional supplement that regulates blood sugar levels in Type II diabetics. It also offers Citroxin, a surface cleaner and an antiviral composition against swine influenza virus and avian influenza viruses; Cinnechol, a nutritional supplement to maintain normal cholesterol levels, as well as to support normal cardiovascular function; Cyclesurface3 cosmetics, a lipophilic surface treatment technology that is used to improve the dispersion of pigments in aqueous and organic materials; and Infinitink, a removable tattoo ink. In addition, the company provides Last Shot Hangover Remedy, a liquid nutritional supplement to help the body combat symptoms that are associated with alcohol-induced hangovers, including nausea, fatigue, and headache; Oraphyte, a nematocide; Prevorex, a liquid dietary supplement designed to help overweight individuals lose weight; purEffect, an acne treatment solution; and Talsyn-CI scar cream. It sells its products through retailers and distributors. The company was formerly known as eFoodSafety.com, Inc. and changed its name to Nuvilex Inc. in March 2009. Nuvilex Inc. is headquartered in Cherry Hill, New Jersey.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company’s lead products include: Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink?, a permanent yet more easily removable tattoo ink. The Company’s complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink?. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit http://www.nuvilex.com/ for additional information on the Company.

I believe this might be worth looking into
Might be a good opportunity started out on the dip
As of now its on the up tick + 3.20%
RSI LINE @ 44.55
Showing positive signs
Keep an eye on it

Press Release Source: Nuvilex, Inc. On Tuesday February 2, 2010, 4:15 pm EST
CHERRY HILL, N.J.--(BUSINESS WIRE)--Nuvilex, Inc. (OTC Bulletin Board: NVLX - News), announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has received its National Drug Code numbers (50107-100-00, 50107-200-00, and 50107-300-00), from the Food and Drug Administration (FDA) for its homeopathic flu remedy. A National Drug Code (NDC) is a universal identifier of any product that is to be marketed as a drug for human use within the United States. The Drug Listing Act of 1972 states that all registered drug establishments must provide to the FDA a current list of all drugs manufactured, prepared, propagated, compounded, or processed by the establishment for commercial distribution.
As a registered homeopathic medicine, Reme-Flu™ is intended for use at the onset of flu or flu-like symptoms and contains ingredients widely recognized to reduce and/or shorten flu or flu-like symptoms. Legacy Biotechnologies’ Syn-X9™ formulation enhances the body’s utilization of Reme-Flu's™ active ingredients.
With the issuance of the NDC for Reme-Flu™, Legacy Biotechnologies is now preparing to manufacture, market and sell Reme-Flu™ for the spring 2010 flu season. Further details on Legacy’s marketing plans will be forthcoming.
“Legacy Biotechnologies has undertaken the appropriate and necessary steps to register Reme-Flu™ with the FDA insuring that Reme-Flu™, its labeling and packaging meet FDA standards for homeopathic remedies,” stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc. “The registration process for Reme-Flu™ was exacting and time consuming, but was necessary in order to ensure that Reme-Flu™ could legally enter the marketplace. We greatly appreciate Legacy Biotechnologies’ building, registering and launching Reme-Flu™ with a commitment to quality, performance and customer satisfaction.”